RecruitingNCT05318755
China Gender-affirming Hormone Therapy Study
Studying NON RARE IN EUROPE: Gender dysphoria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University Third Hospital
- Principal Investigator
- Tianpei Hong, PhD., M.D.Department of Endocrinology and Metabolism, Peking University Third Hospital
- Intervention
- GAHT for transgender men(drug)
- Enrollment
- 240 enrolled
- Eligibility
- 18-40 years · All sexes
- Timeline
- 2022 – 2028
Study locations (1)
- Peking University Third Hospital, Beijing, Beijing Municipality, China
Collaborators
Tsinghua University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05318755 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Gender dysphoria
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07252687The Effect of Gender-affirmative Measures on Breast Perception in Trans MenMedical University Innsbruck
- RECRUITINGNCT07286123Gender Affirming Vaginoplasty With Tubularized Augmented Peritoneal Cap (TAPCap) Utilizing Fish Skin Xenograft (Kerecis™)University Hospitals Cleveland Medical Center
- RECRUITINGNANCT07187947Cardiovascular Health of Transgender Individuals During the Gender-affirming PathwayIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06670053Puberty, Testosterone, and Brain DevelopmentUniversity of Colorado, Denver
- RECRUITINGPHASE3NCT04979338Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming SurgeriesCedars-Sinai Medical Center